Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen TEZSPIRE (tezepelumab-ekko by Quarter
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Rest of World (ROW) product sales ($M) ($M)
Amgen TEZSPIRE (tezepelumab-ekko: $0M in Q2 2026. That is the highest of the 14 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0 | – | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 0 | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 0 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 0 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | – | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 0 | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 0 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 0 | – | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | – | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | – | Form 10-Q (filed 2024-05-03) ↗ |
Cite this data
StockData. (2026). Amgen TEZSPIRE (tezepelumab-ekko ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tezspire-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.